选择性雌激素受体调节剂组织选择性激动剂/拮抗剂活性的分子和细胞机制的定义。

D. McDonnell, Caroline Connor, A. Wijayaratne, Ching-Yi Chang, J. Norris
{"title":"选择性雌激素受体调节剂组织选择性激动剂/拮抗剂活性的分子和细胞机制的定义。","authors":"D. McDonnell, Caroline Connor, A. Wijayaratne, Ching-Yi Chang, J. Norris","doi":"10.1210/RP.57.1.295","DOIUrl":null,"url":null,"abstract":"The term selective estrogen receptor modulators describes a group of pharmaceuticals that function as estrogen receptor (ER) agonists in some tissues but that oppose estrogen action in others. Although the name for this class of drugs has been adopted only recently, the concept is not new, as compounds exhibiting tissue-selective ER agonist/antagonist properties have been around for nearly 40 years. What is new is the idea that it may be possible to capitalize on the paradoxical activities of these drugs and develop them as target organ-selective ER agonists for the treatment of osteoporosis and other estrogenopathies. This realization has provided the impetus for research in this area, the progress of which is discussed in this review.","PeriodicalId":21099,"journal":{"name":"Recent progress in hormone research","volume":"1 1","pages":"295-316"},"PeriodicalIF":0.0000,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"128","resultStr":"{\"title\":\"Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators.\",\"authors\":\"D. McDonnell, Caroline Connor, A. Wijayaratne, Ching-Yi Chang, J. Norris\",\"doi\":\"10.1210/RP.57.1.295\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The term selective estrogen receptor modulators describes a group of pharmaceuticals that function as estrogen receptor (ER) agonists in some tissues but that oppose estrogen action in others. Although the name for this class of drugs has been adopted only recently, the concept is not new, as compounds exhibiting tissue-selective ER agonist/antagonist properties have been around for nearly 40 years. What is new is the idea that it may be possible to capitalize on the paradoxical activities of these drugs and develop them as target organ-selective ER agonists for the treatment of osteoporosis and other estrogenopathies. This realization has provided the impetus for research in this area, the progress of which is discussed in this review.\",\"PeriodicalId\":21099,\"journal\":{\"name\":\"Recent progress in hormone research\",\"volume\":\"1 1\",\"pages\":\"295-316\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2002-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"128\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recent progress in hormone research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1210/RP.57.1.295\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent progress in hormone research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/RP.57.1.295","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 128

摘要

选择性雌激素受体调节剂这一术语描述了一组药物,它们在某些组织中起雌激素受体激动剂的作用,但在其他组织中起反对雌激素的作用。虽然这类药物的名称最近才被采用,但这个概念并不新鲜,因为具有组织选择性内质网激动剂/拮抗剂特性的化合物已经存在了近40年。新的想法是,利用这些药物的矛盾活性,并将其开发为靶向器官选择性内质网激动剂,以治疗骨质疏松症和其他雌激素病变,这是可能的。这一认识为这一领域的研究提供了动力,本文对这一领域的研究进展进行了综述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators.
The term selective estrogen receptor modulators describes a group of pharmaceuticals that function as estrogen receptor (ER) agonists in some tissues but that oppose estrogen action in others. Although the name for this class of drugs has been adopted only recently, the concept is not new, as compounds exhibiting tissue-selective ER agonist/antagonist properties have been around for nearly 40 years. What is new is the idea that it may be possible to capitalize on the paradoxical activities of these drugs and develop them as target organ-selective ER agonists for the treatment of osteoporosis and other estrogenopathies. This realization has provided the impetus for research in this area, the progress of which is discussed in this review.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信